Neostigmine Bromide

溴新斯的明

Report date: 2022/08/25 14:03:59
NME

Base Information

Drug NameNeostigmine Bromide
Drug Alias Name溴化新斯的明bromuro de neostigminaneostigmini bromidum普鲁色林Prostigmin
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAcetylcholinesterase inhibitorsMuscle relaxation antagonists
TargetsAcetylcholinesterase
Therapy Area/IndicationsHypoxiaFlatulenceHeadache +[9] 
Global Approved IndicationsFlatulenceUrinary RetentionMyasthenia Gravis
Approved Indications in ChinaFlatulenceUrinary RetentionMyasthenia Gravis
Original Approved Country/TerritoryMainland China
Original Approved Date1995/01/01
Country/TerritoryPakistanEgyptMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesZiauddin Medical University Usa IncShanghai Sine Pharmaceutical Laboratories Co Ltd
Inactive CompaniesCairo University
Active IndicationsHypoxiaFlatulenceDelayed Emergence from Anesthesia +[8] 
Inactive IndicationsHeadache

Other Information

ATC CodeN07AA01S01EB06
Related LinksWikipediaDrugBankKEGG